BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,775 | +51.4% | 3,358 | +50.6% | 0.01% | 0.0% |
| Q2 2023 | $15,699 | +51.6% | 2,230 | +79.5% | 0.01% | +66.7% |
| Q1 2023 | $10,358 | -70.2% | 1,242 | -59.0% | 0.00% | -75.0% |
| Q4 2022 | $34,796 | +216.3% | 3,031 | +180.1% | 0.01% | +71.4% |
| Q2 2022 | $11,000 | -15.4% | 1,082 | +31.8% | 0.01% | 0.0% |
| Q1 2022 | $13,000 | +44.4% | 821 | +20.2% | 0.01% | +75.0% |
| Q4 2021 | $9,000 | -10.0% | 683 | -5.1% | 0.00% | -33.3% |
| Q3 2021 | $10,000 | -41.2% | 720 | -32.5% | 0.01% | -45.5% |
| Q2 2021 | $17,000 | +240.0% | 1,066 | +112.8% | 0.01% | +37.5% |
| Q1 2021 | $5,000 | – | 501 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |